STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.
The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.
STERIS plc executive John P. Ubbing, Vice President, Chief Compliance & Quality Officer, reports his beneficial ownership in the company as of early 2026. He directly holds 4,230 ordinary shares, of which 2,952 are restricted. These restrictions are scheduled to lapse in stages: 660 shares on May 31, 2026; 1,128 shares on June 2, 2026; 588 shares on June 4, 2027; and 576 shares on June 3, 2028.
In addition, Ubbing has an indirect interest in 248 ordinary share equivalents held for him under the STERIS Corporation 401(k) Plan. He also holds several employee stock options: 2,480 options at an exercise price of $219.97 expiring May 31, 2033; 2,008 options at $251.34 expiring June 4, 2034; and 2,056 options at $267.66 expiring June 3, 2035, each with multi-year vesting schedules that gradually become exercisable.
STERIS plc (STE) reported insider transactions by its Sr. VP and GM, Life Sciences, on November 21, 2025. The officer exercised employee stock options to buy 2,872 ordinary shares at $114.22 and 2,136 ordinary shares at $147.05, then sold the same numbers of shares in two sales at $262 per share. Following these transactions, the officer beneficially owned 10,710 ordinary shares.
As of November 21, 2025, 4,003 of these 10,710 ordinary shares are restricted, with restrictions scheduled to lapse in several tranches between June 1, 2026 and June 5, 2028. The reported stock options are described as fully vested and now show 0 derivative securities remaining after the exercises.
STERIS plc (STE) insider filed a Form 144 to sell 5,008 ordinary shares. The planned sale is through Charles Schwab & Co., Inc. on the NYSE, with an approximate sale date of 11/21/2025. The shares listed have an aggregate market value of $1,312,096.00, and the table notes 98,147,009 shares outstanding. The seller acquired these shares on 11/21/2025 through an employee stock option exercise, using a broker payment for a cashless exercise.
STERIS plc (STE) officer and V.P. & Corporate Treasurer reported option exercises and share sales. On November 18, 2025, the insider exercised an employee stock option for 3,536 ordinary shares at an exercise price of $182.22 per share, then sold shares in several transactions at market prices around the mid-$250s. Reported sales included 3,324 shares at a weighted average price of $257.43, 212 shares at a weighted average price of $258.03, and 1,500 shares at $257.76 per share.
After these transactions, the reporting person beneficially owned 5,695 ordinary shares, including 1,475 restricted shares as of November 18, 2025. The restricted shares are scheduled to vest in installments between June 1, 2026 and June 5, 2028, and the reported stock option is now fully vested with no remaining balance.
STERIS plc (STE) insider activity is disclosed in a Form 144 notice indicating an intention to sell 5,036 ordinary shares. The planned sale, through Charles Schwab & Co., Inc., has an aggregate market value of $1,297,033 and is expected to occur around 11/18/2025 on the NYSE. The company reports 98,147,009 shares outstanding, so this planned sale represents a small portion of total shares.
The securities to be sold were acquired mainly through equity compensation from STERIS plc, including an employee stock option exercise of 3,536 shares on 11/18/2025 via a broker-assisted cashless exercise and several restricted stock lapses between 05/31/2023 and 10/01/2024. The notice also reports that the same holder sold 3,204 shares of STERIS on 08/20/2025 for gross proceeds of $798,560 in the past three months.
STERIS plc (STE) Form 4: The company’s Senior Vice President, General Counsel and Secretary exercised 15,000 employee stock options at $69.72 per share on 11/11/2025 and sold 15,000 ordinary shares the same day at a weighted average price of $265.14 (range $265.00–$265.95). Following these transactions, the officer directly owned 33,669 shares as of 11/11/2025. Of these, 8,511 are restricted, with scheduled lapses through June 2028.
STERIS plc received a Form 144 notice for a proposed sale of 15,000 Ordinary shares. The filing lists an aggregate market value of $3,977,050 and an approximate sale date of 11/11/2025. The designated broker is Charles Schwab & Co., Inc., and the shares are to be sold on the NYSE.
The shares were acquired on 11/11/2025 via an employee stock option exercise with a broker payment for cashless exercise. This notice reflects an intended disposition by a holder under Rule 144.
STERIS plc reported stronger quarterly results for the three months ended September 30, 2025. Revenue rose to $1,460.3 million from $1,328.9 million as Healthcare delivered $1,033.8 million, Applied Sterilization Technologies $281.5 million, and Life Sciences $145.0 million. Operating income increased to $265.8 million from $219.7 million, with net income attributable to shareholders of $191.9 million (diluted EPS $1.94) versus $150.0 million ($1.51) a year ago. The effective tax rate was 23.9%.
Through six months, operating cash flow was $707.8 million, funding capital spending of $180.1 million and supporting cash balances of $319.2 million. Total debt declined to $1,897.3 million from $2,043.7 million. The company repurchased 0.4 million shares for $100.0 million and paid dividends of $1.20 per share year-to-date. Remaining performance obligations were $1,926.4 million, with approximately 53% expected to be recognized within one year.
STERIS plc furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025, which is its fiscal 2026 second quarter. The press release is attached as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is being furnished to the SEC, not deemed “filed” under Section 18 of the Exchange Act, and is not incorporated by reference into Securities Act filings.
Massachusetts Financial Services Company filed an amended Schedule 13G reporting its beneficial ownership in STERIS plc (STE).
MFS reported beneficial ownership of 4,846,124 shares of STERIS common stock, representing 4.9% of the class as of the reported event date. The firm disclosed sole voting power over 4,674,537 shares and sole dispositive power over 4,846,124 shares, with no shared voting or shared dispositive power.
The filing certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of STERIS.